Chikungunya Interpretation
Use
Interpretation of testing aids in diagnosing recent infection with Chikungunya virus in patients with recent travel to endemic areas and a compatible clinical syndrome. The virus is endemic in Africa, India, and recently in the Caribbean islands. Symptoms include high fever, joint pain, and rash. The disease is transmitted by Aedes species mosquitos, with humans as the primary reservoir. Once exposed, individuals develop lasting immunity.
Special Instructions
Not provided.
Limitations
Specimens collected too early after infection may be negative for antibodies to Chikungunya virus. Testing of convalescent serum is recommended. Chikungunya and Dengue viruses co-circulate in endemic areas, and infections can present similarly. Evaluate at-risk patients for both viruses.
New York Approved
Methodology
Automated Analyzer (Clinical Chemistry)
Biomarkers
IgM and IgG Chikungunya antibodies
Analyte
LOINC Codes
- 69048-7 - Immunologist review
- 69048-7 - Immunologist review
Result Turnaround Time
1-14 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
Not provided
Minimum Volume
Not provided
Stability Requirements
| Temperature | Period |
|---|---|
| Refrigerated | 30 days |
| Frozen | 30 days |